Literature DB >> 11887805

Glucose degradation products in peritoneal dialysis fluids: how they can be avoided.

A Wieslander1, T Linden, P Kjellstrand.   

Abstract

OBJECTIVES: A patient on peritoneal dialysis (PD) uses 3-7 tons of PD fluid every year. The result is considerable stress on the peritoneal tissue. Aspects of PD fluids that have been considered responsible for bioincompatibility are low pH, high osmolality, high glucose and lactate concentrations, and the presence of glucose degradation products (GDPs). However, the relative importance of each factor in PD fluid has so far not been investigated. Discovering their relative importance was the aim of the present study.
METHODS: Two main methods for investigating biocompatibility were used in this study: cytotoxicity measured as in vitro inhibition of cell growth, and in vitro AGE formation measured as albumin-linked fluorescence.
RESULTS: The two most important factors for determining in vitro bioincompatibility of PD fluids were the presence of GDPs, which caused both severe cytotoxicity and strong AGE promotion, and low pH, which induced severe cytotoxicity.
CONCLUSIONS: The biocompatibility of PD fluids can be monitored through fairly simple in vitro methods such as cell proliferation and AGE formation. Bioincompatibility of PD fluids is caused mainly by the presence of GDPs and low pH. These findings correlate well with known clinical bioincompatibility.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11887805

Source DB:  PubMed          Journal:  Perit Dial Int        ISSN: 0896-8608            Impact factor:   1.756


  7 in total

Review 1.  Glucose degradation products (GDP's) and peritoneal changes in patients on chronic peritoneal dialysis: will new dialysis solutions prevent these changes?

Authors:  Murali Krishnan; Paul Tam; George Wu; Andrzej Breborowicz; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

2.  The balANZ study--strengthening the evidence for neutral-pH solutions low in glucose degradation products.

Authors:  Martin Wilkie
Journal:  Perit Dial Int       Date:  2012 Sep-Oct       Impact factor: 1.756

3.  A new neutral-pH low-GDP peritoneal dialysis fluid.

Authors:  Rainer Himmele; Lynn Jensen; Dominik Fenn; Chih-Hu Ho; Dixie-Ann Sawin; Jose A Diaz-Buxo
Journal:  Perit Dial Int       Date:  2012-03-01       Impact factor: 1.756

4.  Biocompatibility of a new PD solution for Japan, Reguneal™, measured as in vitro proliferation of fibroblasts.

Authors:  Bart Dioos; Goedele Paternot; Rose-Marie Jenvert; Annick Duponchelle; Mark R Marshall; Migaku Nakajima; Edward Ramirez Ganoza; James A Sloand; Anders P Wieslander
Journal:  Clin Exp Nephrol       Date:  2018-06-20       Impact factor: 2.801

5.  Effect of balance Solution on the Peritoneal Membrane in Automated Peritoneal Dialysis.

Authors:  Tatiana De Los Ríos; Juan Pérez-Martínez; Jose Portoles; Monika Lichodziejewska-Niemierko; Maite Rivera; Michał Nowicki; Andrzej Książek; Ana María Tato; Christine Bohnhorst; Mariano Feriani
Journal:  Perit Dial Int       Date:  2016 9-10       Impact factor: 1.756

6.  Treatment of severe ultrafiltration failure with nonglucose dialysis solutions in patients with and without peritoneal sclerosis.

Authors:  Watske Smit; Marja M Ho-Dac-Pannekeet; Raymond T Krediet
Journal:  NDT Plus       Date:  2008-10

7.  Cross-omics comparison of stress responses in mesothelial cells exposed to heat- versus filter-sterilized peritoneal dialysis fluids.

Authors:  Klaus Kratochwill; Thorsten O Bender; Anton M Lichtenauer; Rebecca Herzog; Silvia Tarantino; Katarzyna Bialas; Achim Jörres; Christoph Aufricht
Journal:  Biomed Res Int       Date:  2015-10-01       Impact factor: 3.411

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.